Author

C. Nitsche

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Assay:proteomics· 3 Organism:virus· 3 Approach:deep learning· 1 Research Focus:protein folding & dynamics· 1 Approach:statistical model· 1

Frequent Co-Authors

S. Ullrich· 4 shared C. J. Jackson· 2 shared G. Otting· 2 shared J. Johansen-Leete· 2 shared R. J. Payne· 2 shared A. Aggarwal· 1 shared A. Ashhurst· 1 shared J. Ton· 1 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 34 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBiochemistry

S. Ullrich

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Phage-Encoded Bismuth Bicycles: Instant Access to Targeted Bioactive Peptides

S. Ullrich, U. Somathilake, M. Shang, C. Nitsche

This paper introduces a method to create bicyclic peptides using bismuth and arsenic in phage display, showing improved binding affinity over linear peptides.

bioRxiv · Apr 10, 2024Biochemistry

Predicting antiviral resistance mutations in SARS-CoV-2 main protease with computational and experimental screening

V. M. Sasi, S. Ullrich, J. Ton, S. E. Fry, J. Johansen-Leete, R. J. Payne, C. Nitsche, C. J. Jackson

This study identifies resistance mutations in SARS-CoV-2 main protease to the drug Nirmatrelvir using computational screening and experimental validation.

Biochemistry · Nov 3, 2022Peer-reviewedBiochemistry

Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir (PF-07321332)

S. Ullrich, K. B. Ekanayake, G. Otting, C. Nitsche

This study shows that nirmatrelvir remains effective against Mpro variants from current SARS-CoV-2 lineages.

bioRxiv · Nov 28, 2021Biochemistry

Discovery of Antiviral Cyclic Peptides Targeting the Main Protease of SARS-CoV-2 via mRNA Display

J. Johansen-Leete, S. Ullrich, S. Fry, R. Frkic, M. Bedding, A. Aggarwal, A. Ashhurst, K. Ekanayake, M. Mahawaththa, V. Sasi, T. Passioura, M. Larance, G. Otting, S. G. Turville, C. J. Jackson, , R. J. Payne

This study identifies cyclic peptides targeting SARS-CoV-2 main protease using mRNA display, showing antiviral activity in vitro.

bioRxiv · Aug 23, 2021Biochemistry